MedPath

Efficacy of Vonoprazan, Sitafloxacin and Amoxicillin Regimen for Treatment of Refractory Helicobacter pylori infectio

Phase 3
Conditions
Prevalence of helicobacter pylori is 17-55%. Ten to twenty percents of H.pylori infection were failed to treatment with first line regimen. Refractory H.pylori infection defined as H.pylori infection which failed to treatment with at least 2 regimens. There was not standard regimen for H.pylori infection.
Refractory Helicobacter pylori, Helicobacter pylori, Resistant Helicobacter pylori
Registration Number
TCTR20211203002
Lead Sponsor
Routine to Research Unit, Siriraj Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
20
Inclusion Criteria

Patient with refractory H.pylori defined as failed to at least 2 H.pylori eradication regimens

Exclusion Criteria

- Patient with history to sitafloxacin, amoxycillin or vonoprazan allergy
- Pregnancy
- Patient with immunodeficiency, decompensated cirrhosis and end stage renal disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy (eradication rate of VAS regimen) 4 weeks after intervention Percentage of successful eradication
Secondary Outcome Measures
NameTimeMethod
Characteristic of Refractory H.pyloi infection patients at the begin of study Age, sex, antibiotic susceptibility of H.pylori, CYP2C19 polymorphism
© Copyright 2025. All Rights Reserved by MedPath